MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks

GSK seeks additional asthma indication for Trelegy Ellipta

October 3, 2019 By Sean Whooley Leave a Comment

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said yesterday that they filed a supplemental New Drug Application with the FDA, seeking an additional indication for GSK’s Trelegy Ellipta inhaler for the treatment of asthma in adults. The once-daily, single-inhaler triple-therapy device received FDA approval for the treatment of chronic obstructive pulmonary disease in September 2017. Trelegy Ellipta has not […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory Tagged With: GlaxoSmithKline plc, Innoviva

Judge adds $10m in damages in Vectura-GSK patent spat

September 16, 2019 By Nancy Crotti Leave a Comment

This article has been updated with a statement from Glaxo Smith Kline. A federal judge in Delaware has awarded British inhaler company Vectura an additional $10.5 million in compensatory damages from Glaxo Smith Kline (NYSE:GSK) in a patent dispute. In May, a jury awarded Vectura $89.7 million in damages for the period from August 2016 through December 2018 for an infringement […]

Filed Under: Drug-Device Combinations, Featured, Legal News, News Well, Respiratory Tagged With: GlaxoSmithKline plc, Vectura

Vectura seeks another $44M in GSK patent win

June 28, 2019 By Nancy Crotti Leave a Comment

Fresh off its $89.7 million jury award in a patent infringement case against GlaxoSmithKline (NYSE:GSK), British inhaler company Vectura has petitioned the court for an additional $44 million. On May 16, a jury in U.S. District Court for the District of Delaware awarded Vectura damages for the period from August 2016 through December 2018 for an infringement […]

Filed Under: Drug-Device Combinations, Featured, Legal News, News Well, Respiratory Tagged With: GlaxoSmithKline plc, Vectura

Thermo Fisher to buy Irish drug manufacturing site from GSK for $101m

May 16, 2019 By Fink Densford Leave a Comment

Thermo Fisher Scientific‘s (NYSE:TMO) said today that it inked a deal to acquire a Cork, Ireland-based drug substance manufacturing site from GlaxoSmithKline (NYSE:GSK) for approximately $100.6 million (EU €90 million). Waltham, Mass.-based Thermo Fisher said that the acquisition of the new site will allow it to expand capacity and meet customer demand for both the development and […]

Filed Under: Business/Financial News, Pharmaceutical, Wall Street Beat Tagged With: GlaxoSmithKline plc, Thermo Fisher Scientific

Vectura wins $89.7m in patent infringement case against GlaxoSmithKline

May 6, 2019 By Danielle Kirsh Leave a Comment

Vectura said this week that it has settled a U.S. patent infringement litigation with GlaxoSmithKline and was awarded $89.7 million in damages. Following a jury trial in the U.S. District Court for the District of Delaware, Ventura was awarded damages for the period from August 2016 through December 2018 for an infringement on Vectura’s U.S. […]

Filed Under: Legal News Tagged With: GlaxoSmithKline plc, Vectura

Innoviva-GSK project Trelegy Ellipta meets main endpoint in asthma pivotal trial

May 6, 2019 By Brad Perriello Leave a Comment

A combination drug-device therapy developed by GlaxoSmithKline(NYSE:GSK) and Innoviva (NSDQ:INVA) for asthma, Trelegy Ellipta, met the primary endpoint in its pivotal trial, the companies said last week. The Trelegy Ellipta inhaler is designed to deliver a single daily dose of three drugs – fluticasone furoate, umeclidinium and vilanterol – to patients with uncontrolled asthma. The 2,436-patient Captain trial […]

Filed Under: Clinical Trials, Drug-Device Combinations, Respiratory Tagged With: GlaxoSmithKline plc, Innoviva

Touting pricetag, Mylan launches Advair generic

February 12, 2019 By Sarah Faulkner Leave a Comment

Mylan (NSDQ:MYL) today announced the launch of its Wixela Inhub product, a generic for GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus device, for people with asthma or chronic obstructive pulmonary disease. The company touted that its device’s list price is 70% less than Advair Diskus and 67% less than GSK’s generic. Get the full story at our sister site, Drug Delivery […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceutical, Wall Street Beat Tagged With: GlaxoSmithKline plc, Mylan

Mylan wins race for generic Advair approval

January 31, 2019 By Nancy Crotti Leave a Comment

FDA has approved the first generic of GlaxoSmithKline‘s (NYSE:GSK) blockbuster Advair respiratory drug, this one by Mylan (NSDQ:MYL), six months after rejecting Mylan’s application. Canonsburg, PA-based Mylan’s shares jumped 7% to $30.82 at market close after yesterday’s late-afternoon announcement, and were trading at $30.96 mid-morning today. GSK’s stock dipped 2% to$38.70 on the news late yesterday, but had more than […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Respiratory Tagged With: FDA, GlaxoSmithKline plc, Mylan, Novartis

NeuroMetrix lands $4m milestone payment from GSK deal

August 23, 2018 By Sarah Faulkner Leave a Comment

NeuroMetrix (NSDQ:NURO) said this week that it reeled in a $3.8 million milestone payment from its collaboration with GlaxoSmithKline‘s (NYSE:GSK) consumer healthcare unit. The strategic deal between the two groups was first announced in January this year. According to the terms of the deal, GSK acquired exclusive ownership of NeuroMetrix’s Quell pain-relief device outside the U.S., in exchange for […]

Filed Under: Funding Roundup, Pain Management, Wall Street Beat Tagged With: GlaxoSmithKline plc, Neurometrix

FDA rejects Mylan’s Advair generic in win for GSK

June 14, 2018 By Sarah Faulkner Leave a Comment

Shares in Mylan (NSDQ:MYL) dropped -5% yesterday after the pharmaceutical company revealed that it received the dreaded ‘complete response letter’ from the FDA, denying its application for a generic version of GlaxoSmithKline‘s (NYSE:GSK) blockbuster Advair respiratory drug. Canonsburg, PA-based Mylan noted that the CRL was due to “minor deficiencies” identified in its application and that it expects […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Mylan, Novartis

GSK’s Arnuity Ellipta asthma therapy wins FDA nod for use in kids as young as 5 years old

May 21, 2018 By Sarah Faulkner Leave a Comment

GlaxoSmithKline (NYSE:GSK) won FDA approval for the use of its Arnuity Ellipta inhaler as a once-daily therapy for the maintenance treatment of asthma in children as young as five years old. The pharmaceutical company touted its regulatory win, pointing out that the fluticasone furoate treatment is one of the only once-daily asthma therapies cleared in the […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc

  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS